These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37007869)

  • 1. Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC.
    Lee JM; Wang R; Johnson A; Ogale S; Kent M; Lee JS
    JTO Clin Res Rep; 2023 Apr; 4(4):100487. PubMed ID: 37007869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic outcomes associated with lymph node examination status in early-stage non-small cell lung cancer: a real-world US study using the SEER-Medicare linked database.
    Lee JM; To TM; Wang S; Lin CW; Johnson A; Meyer CS; Lee JS
    Transl Cancer Res; 2024 Apr; 13(4):1821-1833. PubMed ID: 38737679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.
    West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
    J Manag Care Spec Pharm; 2023 Jul; 29(7):749-757. PubMed ID: 37404067
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic Burden of Recurrence in Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer: A Retrospective Study Using Nationwide Claims Data of South Korea.
    Byun JY; Lee JE; Shim YB; Kim J; Lee SY; Shin BR; Yoon NR; Park MH; Lee EK
    Adv Ther; 2023 Feb; 40(2):550-567. PubMed ID: 36404368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Proteinuria and Kidney Function Decline on Health Care Costs and Resource Utilization in Adults With IgA Nephropathy in the United States: A Retrospective Analysis.
    Lerma EV; Bensink ME; Thakker KM; Lieblich R; Bunke M; Rava A; Wang K; Murphy MV; Oliveri D; Amari DT; Cork DMW; Velez JCQ
    Kidney Med; 2023 Sep; 5(9):100693. PubMed ID: 37637862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data.
    Shim YB; Byun JY; Lee JY; Lee EK; Park MH
    PLoS One; 2022; 17(9):e0274876. PubMed ID: 36126084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population.
    Exuzides A; To TM; Abbass IM; Ta JT; Patel AM; Surinach A; Fuller RLM; Luo J
    J Med Econ; 2022; 25(1):722-729. PubMed ID: 35608039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: A real-world retrospective cohort study.
    Wang F; Sansbury L; Ferrante S; Maiese EM; Willson J; Chen CC; Nunna S; Sun K; Kleinman DM
    J Med Econ; 2022; 25(1):182-192. PubMed ID: 35023807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
    Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
    J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
    [No Abstract]   [Full Text] [Related]  

  • 13. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
    Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
    J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
    Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
    [No Abstract]   [Full Text] [Related]  

  • 15. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
    Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
    Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
    Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
    BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma.
    Jang S; Poretta T; Bhagnani T; Harshaw Q; Burke M; Rao S
    Dermatol Ther (Heidelb); 2020 Oct; 10(5):985-999. PubMed ID: 32548707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
    Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
    Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
    Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
    Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States.
    Atallah EL; Maegawa R; Latremouille-Viau D; Rossi C; Guérin A; Wu EQ; Patwardhan P
    J Health Econ Outcomes Res; 2022; 9(2):19-29. PubMed ID: 35979528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.